Calgary, Alberta, Canada, November 10, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 35,697 deferred share units (“DSUs”) to Marvel’s...
Calgary, Alberta – August 18, 2025 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), , a drug discovery company developing novel therapeutics for autism spectrum...
